How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?

被引：1
|
作者：
Takigawa, Nagio [1 ]
机构：
[1] Kawasaki Med Sch, Dept Gen Internal Med 4, Kita Ku, 2-6-1 Nakasange, Okayama 7008505, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
OPEN-LABEL; ACQUIRED-RESISTANCE; CRIZOTINIB; CHEMOTHERAPY; IDENTIFICATION; INHIBITION; MUTATIONS; CERITINIB;
D O I：
10.1016/j.jtho.2018.07.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1438 / 1440
页数：3
相关论文
共 50 条
  • [41] ALK-Positive Non-Small Cell Lung Cancer Mechanisms of Resistance and Emerging Treatment Options
    Steuer, Conor E.
    Ramalingam, Suresh S.
    CANCER, 2014, 120 (16) : 2392 - 2402
  • [42] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09) : 829 - 838
  • [43] Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
    Zhu, Viola
    Ou, S. H.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 509 - 514
  • [44] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [45] Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer
    Koizumi, Tomonobu
    Fukushima, Toshirou
    Tatai, Toshiharu
    Kobayashi, Takashi
    Sekiguchi, Nodoka
    Sakamoto, Akiyuki
    Sasaki, Shigeru
    LUNG CANCER, 2015, 88 (01) : 112 - 113
  • [46] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
    Yu, Hui
    Sun, Si
    Hu, Xingjiang
    Xia, Jinjing
    Wang, Jialei
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
  • [47] Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Morcos, Peter N.
    Nueesch, Eveline
    Jaminion, Felix
    Guerini, Elena
    Hsu, Joy C.
    Bordogna, Walter
    Balas, Bogdana
    Mercier, Francois
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 129 - 138
  • [48] Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy
    Liao, Bin-Chi
    Lin, Chia-Chi
    Shih, Jin-Yuan
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (05) : 274 - 290
  • [49] A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer
    Wang, Wan-Qing
    Xu, Tao
    Zhang, Jing-Jing
    Wang, Yong
    Wang, Yao
    Zhang, Wei
    Zhu, Jian-Guo
    JOURNAL OF THORACIC DISEASE, 2023, 15 (04) : 1935 - 1947
  • [50] Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
    Ock, Chan-Young
    Yoo, Shin-Hye
    Keam, Bhumsuk
    Kim, Miso
    Kim, Tae Min
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05) : 1116 - +
12345